Affimed N.V. (0HL9.L)
USD 0.98
(-10.93%)
USD 0.98
(-10.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 97.15 Million EUR | -51.55% |
| 2022 | 200.51 Million EUR | -10.94% |
| 2021 | 225.13 Million EUR | 28.12% |
| 2020 | 175.72 Million EUR | 56.4% |
| 2019 | 112.35 Million EUR | -3.28% |
| 2018 | 116.17 Million EUR | 169.18% |
| 2017 | 43.15 Million EUR | -11.45% |
| 2016 | 48.73 Million EUR | -38.56% |
| 2015 | 79.32 Million EUR | 89.27% |
| 2014 | 41.9 Million EUR | 544.75% |
| 2013 | 6.5 Million EUR | -9.61% |
| 2012 | 7.19 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 53.17 Million EUR | -24.63% |
| 2024 Q1 | 70.55 Million EUR | -27.38% |
| 2023 Q3 | 120.46 Million EUR | -10.58% |
| 2023 Q4 | 97.15 Million EUR | -19.35% |
| 2023 FY | 97.15 Million EUR | -51.55% |
| 2023 Q1 | 167.95 Million EUR | -16.24% |
| 2023 Q2 | 134.71 Million EUR | -19.79% |
| 2022 FY | 200.51 Million EUR | -10.94% |
| 2022 Q1 | 193.25 Million EUR | -14.16% |
| 2022 Q3 | 236.39 Million EUR | -9.39% |
| 2022 Q4 | 200.51 Million EUR | -15.18% |
| 2022 Q2 | 260.9 Million EUR | 35.01% |
| 2021 Q1 | 270.58 Million EUR | 53.98% |
| 2021 FY | 225.13 Million EUR | 28.12% |
| 2021 Q4 | 225.13 Million EUR | 2.18% |
| 2021 Q3 | 220.33 Million EUR | -11.16% |
| 2021 Q2 | 248.02 Million EUR | -8.34% |
| 2020 Q2 | 101.14 Million EUR | 4.26% |
| 2020 FY | 175.72 Million EUR | 56.4% |
| 2020 Q1 | 97.01 Million EUR | -13.66% |
| 2020 Q4 | 175.72 Million EUR | 62.8% |
| 2020 Q3 | 107.93 Million EUR | 6.71% |
| 2019 Q3 | 85.55 Million EUR | -13.69% |
| 2019 Q2 | 99.11 Million EUR | -10.17% |
| 2019 Q1 | 110.33 Million EUR | -5.02% |
| 2019 FY | 112.35 Million EUR | -3.28% |
| 2019 Q4 | 112.35 Million EUR | 31.34% |
| 2018 Q3 | 49.06 Million EUR | -17.55% |
| 2018 Q2 | 59.51 Million EUR | -10.62% |
| 2018 Q1 | 66.58 Million EUR | 54.29% |
| 2018 FY | 116.17 Million EUR | 169.18% |
| 2018 Q4 | 116.17 Million EUR | 136.76% |
| 2017 Q3 | 45.35 Million EUR | -14.77% |
| 2017 Q4 | 43.15 Million EUR | -4.85% |
| 2017 FY | 43.15 Million EUR | -11.45% |
| 2017 Q2 | 53.21 Million EUR | -6.71% |
| 2017 Q1 | 57.04 Million EUR | 17.04% |
| 2016 FY | 48.73 Million EUR | -38.56% |
| 2016 Q3 | 53.23 Million EUR | -13.64% |
| 2016 Q2 | 61.64 Million EUR | -12.69% |
| 2016 Q1 | 70.6 Million EUR | -11.0% |
| 2016 Q4 | 48.73 Million EUR | -8.45% |
| 2015 FY | 79.32 Million EUR | 89.27% |
| 2015 Q3 | 63.13 Million EUR | -9.59% |
| 2015 Q2 | 69.82 Million EUR | 77.71% |
| 2015 Q1 | 39.29 Million EUR | -6.25% |
| 2015 Q4 | 79.32 Million EUR | 25.65% |
| 2014 Q1 | 7.04 Million EUR | 8.42% |
| 2014 Q3 | 47.86 Million EUR | 961.2% |
| 2014 Q4 | 41.9 Million EUR | -12.43% |
| 2014 Q2 | 4.51 Million EUR | -36.0% |
| 2014 FY | 41.9 Million EUR | 544.75% |
| 2013 Q4 | 6.5 Million EUR | 0.0% |
| 2013 FY | 6.5 Million EUR | -9.61% |
| 2012 FY | 7.19 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | 80.536% |
| Dynavax Technologies Corporation | 997.09 Million USD | 90.256% |
| Cara Therapeutics, Inc. | 125.84 Million USD | 22.796% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.88% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 93.104% |
| Perrigo Company plc | 10.8 Billion USD | 99.101% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | 41.296% |
| Illumina, Inc. | 10.11 Billion USD | 99.039% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.902% |
| Nektar Therapeutics | 398.03 Million USD | 75.591% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 87.55% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 99.636% |
| Heron Therapeutics, Inc. | 222.5 Million USD | 56.335% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -47.902% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 98.58% |
| Waters Corporation | 4.62 Billion USD | 97.9% |
| Biogen Inc. | 26.84 Billion USD | 99.638% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | 41.231% |
| Adicet Bio, Inc. | 207.29 Million USD | 53.131% |
| Evolus, Inc. | 188.99 Million USD | 48.594% |
| bluebird bio, Inc. | 619.16 Million USD | 84.308% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 50.783% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 52.79% |
| FibroGen, Inc. | 423.52 Million USD | 77.06% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 99.097% |
| Homology Medicines, Inc. | 47.05 Million USD | -106.467% |
| Geron Corporation | 394.07 Million USD | 75.346% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 97.463% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -243.646% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 87.51% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 91.895% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 99.706% |
| OPKO Health, Inc. | 2.01 Billion USD | 95.17% |
| Viking Therapeutics, Inc. | 368.49 Million USD | 73.634% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 92.532% |
| Zoetis Inc. | 14.28 Billion USD | 99.32% |
| Abeona Therapeutics Inc. | 64 Million USD | -51.803% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 97.105% |
| Exelixis, Inc. | 2.94 Billion USD | 96.698% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 99.573% |
| uniQure N.V. | 831.68 Million USD | 88.318% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -73.653% |
| Anavex Life Sciences Corp. | 154.38 Million USD | 37.069% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 83.483% |
| Verastem, Inc. | 149.71 Million USD | 35.107% |
| Imunon, Inc. | 21.91 Million USD | -343.274% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 96.751% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 97.024% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 97.012% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 84.368% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 94.395% |
| TG Therapeutics, Inc. | 329.58 Million USD | 70.522% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 90.74% |
| Insmed Incorporated | 1.32 Billion USD | 92.694% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 89.632% |
| Incyte Corporation | 6.78 Billion USD | 98.567% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 94.705% |